News

Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.
A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...
Eli Lilly and Company (LLY) Announces New Phase 3 Trial Results for Orforglipron
Eli Lilly and Company (NYSE:LLY) is one of the Stocks With Huge Catalysts on the Horizon. On July 21, Eli Lilly and Company ...
Eli Lilly’s stock drops as Trump targets 17 drug makers with letters on their pricing
Shares of Eli Lilly & Co. erased gains to trade down nearly 1% after White House press secretary Karoline Leavitt said the company was among 17 drugmakers that will be receiving letters from President ...
What's Going On With Eli Lilly Stock On Tuesday?
Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...
PharmExec3d
Eli Lilly and Company Acquires Vere Therapeutics to Further Develop One-Time Cardiovascular Treatments
Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...
Eli Lilly and Biogen/Eisai’s extension trials make waves in Alzheimer’s market
Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...
Stocktwits on MSN2d
Eli Lilly’s Cancer Drug Demonstrates Better Effectiveness Than AbbVie’s In Late Stage Trial: Retail Believes In Holding The Stock
Eli Lilly and Company (LLY) on Tuesday said that its cancer drug Jaypirca was more effective than AbbVie’s drug Imbruvica in ...
Clinical Trials Arena on MSN1d
Eli Lilly eyes SoC status as Jaypirca proves superior to Imbruvica in CLL/SLL
Eli Lilly’s Jaypirca (pirtobrutinib) has been shown to be superior to Johnson & Johnson (J&J) and AbbVie’s star Bruton's ...